M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.
The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.
CEOs at large pharma and biotech companies are upbeat when it comes to their outlook for both their own company and the industry at large; they also have a healthy appetite for M&A, found a KPMG survey.
Pfizer Inc has started a trial to evaluate its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.
AstraZeneca has announced a long-term research collaboration with VaxEquity for the discovery, development and commercialization of its self-amplifying RNA (saRNA) therapeutics platform.
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.
AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.
French innovator, TreeFrog Therapeutics, which is focused on developing affordable stem cell-derived cell therapies, has just closed a US$75m (€64M) Series B financing round, bringing its total funding to date to US$83m (€70M).
Japan’s health ministry is to secure 150 million doses of Novavax’ vaccine candidate that Takeda is producing. The Japanese government's purchasing agreement is subject to regulatory approvals.
Previously a series of unsuccessful clinical trials for treatments, combined with the high costs of R&D in the area, led to declining interest in dementia research but a new publication from the WHO notes a definite uptick in the funding of such work...
Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.
Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.
Moderna has initiated its submission to the US Food and Drug Administration (FDA) to support the authorization of a booster dose of its mRNA COVID-19 vaccine at the 50-microgram (mcg) dose level.
Anti-CD25 antibodies have emerged as promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.
Special Edition: Reviewing the advanced therapy pipeline
As a relatively new player in the field of cell therapy, Santen Pharmaceutical has outlined how it is looking to collaborate with key stakeholders in order to shape relevant policies, forge meaningful partnerships and create an optimal environment for...
Special Edition: Reviewing the advanced therapy pipeline
Catalent sees COVID-19 vaccines being an 'enduring and sustainable' revenue stream for the company, particularly with the advent of boosters, and the fact that developing countries, to date, have very low vaccination rates.
Seattle-based Umoja Biopharma, a company looking to reprogram immune cells in-vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, has started work on its new development and manufacturing facility...
Boston-based company, Vertex, has signed a deal to use Arbor Biotechnologies’ CRISPR gene-editing technology to develop novel cell therapies for the treatment of serious diseases.
Novartis’s Kymriah CAR-T therapy did not meet its primary endpoint of event-free survival in a phase 3 study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.
Earlier this month, Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced that it had broken ground on its new production facility, adjacent to its existing site in Milford, Massachusetts, in the greater Boston...
VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....
There is “sizable demand” from manufacturers of COVID-19 vaccines for vials out to 2023, suggesting that the market will remain significant for some time.
The World Trade Organization (WTO) Secretariat has published a list of critical inputs for COVID-19 vaccines as part of an effort to address gaps in global production and distribution of the products.
Data presented by Prothena at AAIC on two of its Alzheimer’s disease programs suggests PRX012, its next generation anti-amyloid beta (Aβ) antibody, can clear two types of Aβ plaque in brain tissue, and that its AD vaccine program can simultaneously target...
Novasep has signed a manufacturing services agreement with Exelixis, an oncology-focused US biotechnology company, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC).
Cell therapy player, Bone Therapeutics, has secured up to €16m (US$18.9m) in a financing loan from the European Investment Bank (EIB) to accelerate ongoing clinical and commercial development of innovative orthopedic treatments.
Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.
Simcere has announced a partnership with Vivoryon whereby it will leverage the potential of innovative N3pE amyloid-targeting agents to treat Alzheimer’s disease (AD) in Greater China.
The University of Oxford in partnership with AstraZeneca began vaccinations yesterday for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the Beta [South African] variant.
Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...
Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.
